A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI) - Full Text View

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)

This study has been withdrawn prior to recruitment.
( Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data. )

Sponsored by:	Organon
Information provided by:	Organon
ClinicalTrials.gov Identifier:	NCT00060554

Purpose

The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.

Condition	Intervention	Phase
Myocardial Infarction Coronary Disease	Drug: fondaparinux sodium Drug: heparin Procedure: percutaneous coronary intervention (PCI)	Phase II

MedlinePlus related topics:

Blood Thinners Heart Attack

Drug Information available for:

Fondaparinux sodium ORG 31540 Heparin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Organon:

Estimated Enrollment:	300
Study Start Date:	April 2003

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria

Scheduled for PCI, including PCI for non-ST elevation acute coronary syndromes (ACS), primary PCI for ST elevation myocardial infarction (MI) or elective PCI (with planned overnight stay in hospital). (Patients undergoing diagnostic heart catherization who are suitable candidates for "ad hoc" PCI are also eligible).

Exclusion criteria:

Age < 21 years
Activated Clotting Time (ACT) > 200 seconds immediately prior to PCI
Use of low molecular weight heparin (LMWH) in the previous 6 hours before PCI
Currently receiving an oral anticoagulant (OAC) agent with an INR > 1.8
Thrombolytic therapy for ST elevation MI in the previous 24 hours before PCI
Active internal bleeding or history of hemorrhagic diathesis
Thrombocytopenia (platelet count < 100 x 10-9/L)
Pregnant women or women of childbearing potential who are not using an effective method of contraception
Known allergy to unfractionated heparin, fondaparinux, aspirin or clopidogrel
Absolute contra-indication to anticoagulation
Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment or prior participation in this study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00060554

Show 26 Study Locations

Sponsors and Collaborators

Organon

More Information

Study ID Numbers:	63133 (ASPIRE-Pilot)
First Received:	May 7, 2003
Last Updated:	September 23, 2008
ClinicalTrials.gov Identifier:	NCT00060554
Health Authority:	United States: Food and Drug Administration

Keywords provided by Organon:

Elective PCI

Heart catherization

Acute coronary syndromes

Study placed in the following topic categories:

Heart Diseases

Myocardial Ischemia

Vascular Diseases

Fondaparinux

Ischemia

Org 31540

Calcium heparin

Coronary Disease

Necrosis

Acute Coronary Syndrome

Infarction

Myocardial Infarction

Heparin

Additional relevant MeSH terms:

Fibrin Modulating Agents

Anticoagulants

Pathologic Processes

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Hematologic Agents

Fibrinolytic Agents

Cardiovascular Diseases

Cardiovascular Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008